Amount Raised
$2.3 Million
Round Type
Seed
BostonBiotechnologyHealth CareTherapeuticsDescription
Remedium Bio, Inc., a biotechnology company developing novel gene therapies, today announced that it has closed more than $2.3M in its expanded seed round financing. Funding from the raise is being used to study Remedium's lead product, a single-injection gene therapy potentially capable of reversing cartilage loss, in a collaboration with Tufts University School of Medicine scientists researching rheumatic disorders. The financing was led by Sherwood Ventures and included participation from, LongevityTech.Fund, Primo Medical Group, Angel Star Ventures, Apis Health Angels, MicroVentures, and Guindy Alumni Angels.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Remedium Bio that raised within 45 days of this round, from Fundz verified event records.
- Qnovia raised $17M (Series A) on September 28, 2022.
- Damona Pharmaceuticals raised $5.5M (Seed) on September 28, 2022.
- CLEARA Biotech B.V raised $2.5M (Seed) on September 28, 2022.
- bioAffinity Technologies raised $7.7M (Post-IPO Equity) on September 28, 2022.
- Gamida Cell raised $25M (Funding Round) on September 28, 2022.
- Curavit Clinical Research raised $8.5M on September 28, 2022.
Who to call at Remedium Bio, and when
A new round usually means Remedium Bio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Remedium Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Remedium Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Remedium Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Remedium Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Remedium Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.